Tapentadol Prolonged Release Reduces the Severe Chronic Ischaemic Pain and Improves the Quality of Life in Patients with Type 2 Diabetes

• Published in: Journal of Diabetes Research Vol. 2018; no. 2018; pp. 1 - 6
• Main Authors: Anichini, Roberto, Perini, Marco, Bernini, Arianna, Francia, Piergiorgio, De Bellis, Alessandra, Tedeschi, Anna, Salutini, Elisabetta
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2018; Hindawi; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Aged; Aged, 80 and over; Analgesics; Analgesics - therapeutic use; Chronic illnesses; Chronic Pain - drug therapy; Chronic Pain - etiology; Clinical Study; Delayed-Action Preparations; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetic Angiopathies - complications; Diabetic neuropathy; Disease; Drug dosages; Drug therapy; Female; Foot diseases; Humans; Ischemia; Male; Middle Aged; Narcotics; Pain; Pain - drug therapy; Pain - etiology; Pain Measurement; Patients; Peripheral Arterial Disease - complications; Phenols - administration & dosage; Phenols - therapeutic use; Quality of Life; Questionnaires; Sleep; Tapentadol; Treatment Outcome; Type 2 diabetes; Values
• ISSN: 2314-6745; 2314-6753
• DOI: 10.1155/2018/1081792

This study has been performed in diabetic type 2 patients with pain due to peripheral artery disease (PAD) in order to evaluate the efficacy and tolerability of tapentadol prolonged release (PR). Methods. 25 patients with type 2 diabetes (13 F and 12 M) were admitted in the study. The evaluation of the analgesic efficacy of tapentadol PR was based on both the assessment of the intensity of the pain (NRS scale from 0 to 10) and the nature of the pain (DN4 questionnaire) and on assessment of the patient’s quality of life and state of health (SF-12 Health Survey). Study duration was 3 months: a baseline visit and follow-up included visits after 1 week, 1 month, 2 months, and 3 months. Results. At the beginning of the study, the mean intensity of the pain was 7.88 ± 1.17 on the NRS scale and at visit 2 it reduced in a statistically significant way; at the end of the treatment with tapentadol PR, the mean intensity was 2.84 points on the NRS scale. Conclusion. In type 2 diabetic patients with chronic severe pain due to PAD, tapentadol PR reduced pain intensity, improving the quality of life.